Guardant Health (GH) PT Raised to $125 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts GH Hot Sheet
Price: $168.99 -3.43%
Rating Summary:
30 Buy, 1 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
30 Buy, 1 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Canaccord Genuity analyst Mark Massaro raised the price target on Guardant Health (NASDAQ: GH) to $125.00 (from $96.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Guardant Health adds former Dexcom CEO Kevin Sayer to its board
- United Therapeutics Corp. (UTHR) PT Raised to $720 at Raymond James
- Leidos Holdings (LDOS) PT Lowered to $138 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
